In this report, a fully automated workflow is developed and validated for simultaneous quantification of the cardiovascular disease risk markers apolipoproteins A-I (apoA-I) and B-100 (apoB-100) in clinical sera. By coupling of stableisotope standards and capture by antipeptide antibodies (SISCAPA) for enrichment of proteotypic peptides from serum digests to matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS detection, the standardized platform enables rapid, liquid chromatography-free quantification at a relatively high throughput of 96 samples in 12 h.
The average imprecision in normo-and triglyceridemic serum pools is 3.8% for apoA-I and 4.2% for apoB-100 (four replicates over 5 days). If stored properly, the MALDI target containing enriched apoA-1 and apoB-100 peptides can be reanalyzed without any effect on bias or imprecision for at least 7 days after initial analysis. Validation of the workflow reveals excellent linearity for daily calibration with external, serum-based calibrators (R 2 of 0.984 for apoA-I and 0.976 for apoB-100 as average over 5 days) and absence of matrix effects or interference from triglycerides, protein content, hemolysates, or bilirubins.
Quantification of apoA-I in 93 normo-and hypertriglyceridemic clinical sera shows good agreement with immunoturbidimetric analysis (slope = 1.01, R 2 = 0.95, mean bias = 4.0%). Measurement of apoB-100 in the same clinical sera using both methods, however, reveals several outliers in SISCAPA-MALDI-TOF-MS measurements, possibly as a result of the lower MALDI-TOF-MS signal intensity (slope = 1.09, R 2 = 0.91, mean bias = 2.0%). The combination of analytical performance, rapid cycle time, and automation potential validates the SISCAPA-MALDI-TOF-MS platform as a valuable approach for standardized and high-throughput quantification of apoA-I and apoB-100 in large sample cohorts (Van den Broek, L., et al. Methods 2015, 81, 74-85) .
Automated Processing of Imaging Data through Multitiered Classification of Biological Structures Illustrated Using Caenorhabditis elegans
Quantitative imaging has become a vital technique in biological discovery and clinical diagnostics; a plethora of tools have recently been developed to enable new and accelerated forms of biological investigation. Increasingly, the capacity for high-throughput experimentation provided by new imaging modalities, contrast techniques, microscopy tools, microfluidics, and computer-controlled systems shifts the experimental bottleneck from the level of physical manipulation and raw data collection to automated recognition and data processing. Yet, despite their broad importance, image analysis solutions to address these needs have been narrowly tailored.
In this report, Zhan et al. present a generalizable formulation for autonomous identification of specific biological structures that is applicable for many problems. The process flow architecture presented here uses standard imageprocessing techniques and the multitiered application of classification models such as support vector machines (SVMs). These low-level functions are readily available in a large array of image-processing software packages and programming languages. The framework is thus easy to implement at the modular level and provides specific high-level architecture to guide the solution of more complicated imageprocessing problems.
The authors demonstrate the utility of the classification routine by developing two specific classifiers as a toolset for automation and cell identification in the model organism Caenorhabditis elegans. To serve a common need for automated high-resolution imaging and behavior applications in the C. elegans research community, Zhan et al. contribute a ready-to-use classifier for the identification of the head of the animal under bright-field imaging. Furthermore, the authors extend the framework to address the pervasive problem of cell-specific identification under fluorescent imaging, which is critical for biological investigation in multicellular organisms or tissues. Using these examples as a guide, the authors envision the broad utility of the framework for diverse problems across different length scales and imaging methods (Zhan, M., et al. PLoS Comput. Biol. 2015, 11, e1004194 Multiplex methodologies, especially those with high-throughput capabilities, generate large volumes of data. Accumulation of such data (e.g., genomics, proteomics, metabolomics) is fast becoming more common and thus requires the development and implementation of effective data mining strategies designed for biological and clinical applications.
Multiplex microbead immunoassay (MMIA), on an xMAP or MagPix platform (Luminex), which is amenable to automation, offers a major advantage over conventional methods such as Western blot or enzyme-linked immunosorbent assay (ELISA) for increasing the efficiencies in the serodiagnosis of infectious diseases. MMIA allows detection of antibodies and/or antigens efficiently for a wide range of infectious agents simultaneously in host blood samples, in one reaction vessel. In the process, MMIA generates large volumes of data.
In this report, Mani et al. demonstrate the application of data mining tools on how the inherent large-volume data can improve the assay tolerance (measured in terms of sensitivity and specificity) by analysis of experimental data accumulated over a span of 2 years. The combination of prior knowledge with machine learning tools provides an efficient approach to improve the diagnostic power of the assay on a continuous basis. Furthermore, this study provides an in-depth knowledge base to study pathological trends of infectious agents in mouse colonies on a multivariate scale. Data mining techniques using serodetection of infections in mice, developed in this study, can be used as a general model for more complex applications in epidemiology and clinical translational research (Mani, A., et al. PLoS One 2015, 10, e0116262) .
Dimensional Cell Cultures: A Comparison between Manually and Automatically Produced Alginate Beads
Cancer diseases are a common problem of the population caused by age and increased harmful environmental influences. Herein, new therapeutic strategies and compound screenings are necessary. The regular 2D cultivation has to be replaced by 3D cell culturing for better simulation of in vivo conditions. The 3D cultivation with alginate matrix is an appropriate method for encapsulating cells to form cancer constructs. The automated manufacturing of alginate beads might be an ultimate method for large-scale manufacturing constructs similar to cancer tissue. The aim of this study is the integration of fully automated systems for the production, cultivation, and screening of 3D cell cultures.
Lehmann et al. compare the automated methods with the regular manual processes, and they investigate the influence of antibiotics on these 3D cell culture systems. The alginate beads are formed by automated and manual procedures. The automated steps are processes by the Biomek Cell Workstation from Beckman Coulter (celisca, Rostock, Germany). The proliferation and toxicity are manually and automatically evaluated at days 14 and 35 of cultivation. The results visualize an accumulation and expansion of cell aggregates over the period of incubation. The proliferation and toxicity are decreased on day 35 compared with day 14. The comparison of the manual and automated methods displays similar results. The authors conclude that the manual production process could be replaced by the automation. Using automation, 3D cell cultures can be produced on an industrial scale and improve the drug development and screening to treat serious illnesses such as cancer (Lehmann, R., et al. 
Microfluidic Chip Technology and Microreactor Technology

A Lab-on-a-Chip for Hypoxic Patch Clamp Measurements Combined with Optical Tweezers and Spectroscopy-First Investigations of Single Biological Cells
The response and the reaction of the brain system to hypoxia is a vital research subject that requires special instrumentation. With this research subject in focus, a new multifunctional lab-on-a-chip (LOC) system with control over the oxygen content for studies on biological cells is presented by Alrifaiy et al.
The chip is designed to incorporate the patch-clamp technique, optical tweezers, and absorption spectroscopy. The performance of the LOC is tested by a series of experiments. The oxygen content within the channels of the LOC is monitored by an oxygen sensor and verified by simultaneously studying the oxygenation state of chicken red blood cells (RBCs) with absorption spectra. The chicken RBCs are manipulated optically and steered in three dimensions toward a patch-clamp micropipette in a closed microfluidic channel. The oxygen level within the channels could be changed from a normoxic value of 18% O 2 to an anoxic value of 0.0% to 0.5% O 2 .
A time series of three experiments are performed, showing that the spectral transfer from the oxygenated to the deoxygenated state occurs after about 227 ± 1 s, and a fully developed deoxygenated spectrum is observed after 298 ± 1 s, a mean value of three experiments. The tightness of the chamber to oxygen diffusion is verified by stopping the flow into the channel system while continuously recording absorption spectra showing an unchanged deoxygenated state during 5400 ± 2 s. A transfer of the oxygenated absorption spectra is achieved after 426 ± 1 s when exposing the cells to normoxic buffer. This shows the long time viability of the investigated cells. Successful patching and sealing are established on a trapped RBC, and the whole-cell access (Ra) and membrane (Rm) resistances are measured to be 5.033 ± 0.412 M Ω and 889.7 ± 1.74 M Ω, respectively (Alrifaiy, A., et al. Biomed. Eng. Online 2015, 14, 36 ).
An Implantable Drug-Delivery System on a Chip
Implantable systems for drug delivery provide new strategies for drug therapy and typically involve microfluidic chips produced with micro-or nano-technology. Implantable systems have the flexibility to accommodate various delivery schemes, including zero-order, pulsatile, and on-demand dosing, as opposed to a standard sustained-release profile. Such an implantable system is classified as allowing either controllable or uncontrollable drug release after implantation, so an active or passive delivery system, respectively. The performance and related applications of these systems vary. Key features of each technology are highlighted such as working principles, fabrication methods, dimensional constraints, and performance criteria. The authors review the implantable drug delivery system in current research with a focus on application and chip performance, as well as comparison for passive and active delivery systems (Lee, M. S., et al. Curr. Top. Med. Chem. 2015 , 15, 1516 -1524 .
Building Bio-Assays with Magnetic Particles on a Digital Microfluidic Platform
Digital microfluidics (DMF) has emerged as a promising liquid handling technology for a variety of applications, demonstrating great potential both in terms of miniaturization and automation. DMF is based on the manipulation of discrete, independently controllable liquid droplets, which makes it highly reconfigurable and reprogrammable. One of its most exclusive advantages, compared with microchannel-based microfluidics, is its ability to precisely handle solid nano-and microsized objects, such as magnetic particles.
Magnetic particles have become very popular in the past decade, because their high surface-to-volume ratio and the possibility of magnetically separating them from the matrix make them perfectly suitable as a solid support for bioassay development. The potential of magnetic particles in DMF-based bioassays has been demonstrated for various applications.
In this review, Kokalj et al. discuss the latest developments of magnetic particle-based DMF bioassays with the aim to present, identify, and analyze the trends in the field. The authors also discuss state-of-the art device integration, current status of commercialization, and issues that still need to be addressed. With this article, the authors intend to stimulate researchers to exploit and unveil the potential of these exciting tools, which will shape the future of modern biochemistry, microbiology, and biomedical diagnostics (Kokalj, T., et al. N. Biotechnol. 2015, 32, 485-503) .
Reconfigurable Microfluidic Dilution for HighThroughput Quantitative Assays
This article reports a reconfigurable microfluidic dilution device for high-throughput quantitative assays, which can easily produce discrete logarithmic/binary concentration profiles ranging from 1-to 100-fold dilution in parallel from a fixed sample volume (e.g., 10 µL) without any assistance of a continuous fluidic pump or robotic automation.
The integrated dilution generation chip consists of switchable distribution and collection channels, metering reservoirs, reaction chambers, and pressure-activatable Laplace valves. Following the sequential loading of a sample, a diluent, and a detection reagent into their individual metering chambers, the top microfluidic layer can be reconfigured to collect the metered chemicals into the reaction chambers in parallel, where detection is conducted. To facilitate mixing and reaction in the microchambers, two acoustic microstreaming actuation mechanisms are investigated for easy integrability and accessibility. Plus, the microfluidic dilution generator is characterized by both colorimetric and fluorescent means.
A further demonstration of the generic usage of the quantitative dilution chip uses the commonly available bicinchoninic acid (BCA) assay to analyze the protein concentrations of human tissue extracts. In brief, the microfluidic dilution generator offers a high-throughput, high-efficiency, quantitative analytical alternative to conventional quantitative assay platforms. With simple manipulation of a minute amount of chemicals in a compact microfluidic device with minimal equipment requirement, it can serve as a facile tool for biochemical and biological analyses in regular laboratories, point-of-care settings, and low-resource environments (Fan, J., et al. LabChip 2015 , 15, 2670 -2679 .
Assay Automation Systems
ELISA in the Multiplex Era: Potentials and Pitfalls
Multiplex immunoassays confer several advantages over widely adopted singleplex immunoassays, including increased efficiency at a reduced expense, greater output per sample volume ratios, and higher throughput predicating more resolute, detailed diagnostics and facilitating personalized medicine. Nonetheless, to date, relatively few protein multiplex immunoassays have been validated for in vitro diagnostics in clinical/point-of-care settings.
This review article outlines the challenges, which must be ameliorated prior to the widespread integration of multiplex immunoassays in clinical settings. They include biomarker validation; standardization of immunoassay design and quality control (calibration and quantification); availability, stability, specificity, and cross-reactivity of reagents; assay automation; and the use of validated algorithms for transformation of raw data into diagnostic results.
A compendium of multiplex immunoassays applicable to in vitro diagnostics and a summary of the diagnostic products currently available commercially are included, along with an analysis of the relative states of development for each format (namely planar slide based, suspension, and planar/microtiter plate based) with respect to the aforementioned issues (Tighe, P. J., et al. Proteomics Clin. Appl. 2015, 9, 406-422) .
Protein Microarray Technology: How Far Off Is Routine Diagnostics?
The nature of protein microarray platforms is favorable for multiplexing, leading to the development of tools for personalized medicine and highly precise diagnostics. To date, however, only a limited number of protein microarrays are available in the in vitro diagnostics (IVD) market. This review article focuses on operational challenges that are crucial for the use of microarrays in clinical settings, including probe printing and quality control, procurement of bioreagents and antibody cross-reactivity, mass transport limitations and assay automation, and calibration and quantification. A selection of microarray assays applicable to IVD and a summary of the diagnostic products currently available on the market are provided (Cretich, M., et al. Analyst 2014, 139, 528-542) .
Ultra-High-Throughput Screening of an In VitroSynthesized Horseradish Peroxidase Displayed on Microbeads Using Cell Sorter
The C1a isoenzyme of horseradish peroxidase (HRP) is an industrially important heme-containing enzyme that uses hydrogen peroxide to oxidize a wide variety of inorganic and organic compounds for practical applications, including synthesis of fine chemicals, medical diagnostics, and bioremediation. To develop an ultra-high-throughput screening system for HRP, Zhu et al. successfully produce active HRP in an Escherichia coli cell-free protein synthesis system by adding disulfide bond isomerase DsbC and optimizing the concentrations of hemin and calcium ions and the temperature.
The biosynthesized HRP is fused with a single-chain Cro (scCro) DNA-binding tag at its N-terminal and C-terminal sites. The addition of the scCro-tag at both ends increases the solubility of the protein. Next, HRP and its fusion proteins are successfully synthesized in a water droplet emulsion by using hexadecane as the oil phase and SunSoft No. 818SK as the surfactant. HRP fusion proteins are displayed on microbeads attached with double-stranded DNA (containing the scCro binding sequence) via scCro-DNA interactions.
The activities of the immobilized HRP fusion proteins are detected with a tyramide-based fluorogenic assay using flow cytometry. Moreover, a model microbead library containing wild-type hrp (WT) and inactive mutant (MUT) genes is screened using fluorescence-activated cell sorting, thus efficiently enriching the WT gene from the 1:100 (WT:MUT) library. The technique described here could serve as a novel platform for the ultra-high-throughput discovery of more useful HRP mutants and other hemecontaining peroxidases (Zhu, B., et al. PLoS One 2015, 10, e0127479) .
Advances in Clinical Automation
Automated CD34+ Cell Isolation of Peripheral Blood Stem Cell Apheresis Product
Immunomagnetic enrichment of CD34+ hematopoietic stem cells (HSCs) using paramagnetic nanobead coupled CD34 antibody and immunomagnetic extraction with the CliniMACS plus system is the standard approach to generating T-cell-depleted stem cell grafts. Their clinical beneficence in selected indications is established. Even though CD34+ selected grafts are typically given in the context of a severely immunosuppressive conditioning with anti-thymocyte globulin or similar, the degree of T-cell depletion appears to affect clinical outcomes, and thus in addition to CD34 cell recovery, the degree of T-cell depletion critically describes process quality.
An automatic immunomagnetic cell processing system, CliniMACS Prodigy, including a protocol for fully automatic CD34+ cell selection from apheresis products, is presented by Spohn et al., who perform a formal process validation to support submission of the protocol for CE release, a prerequisite for clinical use of Prodigy CD34+ products. Granulocyte colony-stimulating factor-mobilized healthy-donor apheresis products are subjected to CD34+ cell selection using Prodigy with clinical reagents and consumables and advanced beta versions of the CD34 selection software. Target and nontarget cells are enumerated using sensitive flow cytometry platforms.
Nine successful clinical-scale CD34+ cell selections are performed. Beyond setup, no operator intervention is required. Prodigy recovers 74% ± 13% of target cells with a viability of 99.9% ± 0.05%. Per 5 × 10E6 CD34+ cells, which the authors consider a per-kilogram dose of HSCs, products contained 17 ± 3 × 10E3 T cells and 78 ± 22 × 10E3 B cells.
The process for CD34 selection with Prodigy is robust and labor saving but not time saving. Compared with clinical CD34+ selected products concurrently generated with the predecessor technology, product properties, importantly including CD34+ cell recovery and T-cell contents, are not significantly different. The automatic system is suitable for routine clinical application (Spohn, G., et al. Cytotherapy 2015 May 14 [Epub ahead of print]).
